For the past several years, there has been increased interest in the concept of the co-creation of new knowledge as an approach to more effectively operationalising models of research translation. Co-creation of new knowledge has the potential to combat research waste, increase the research capacity of service providers and improve service delivery.
But what is the co-creation of new knowledge?
Around one in two people who inject drugs (PWID) have been exposed to hepatitis C virus (HCV) and potentially 6 million PWID globally are chronically infected.
A relatively neglected source of day-to-day ill-health among people who inject drugs is bacterial infections of the skin and soft tissue (SSTIs). Usually when we talk about infections among people who inject drugs, we are talking about blood borne viral infections, such as HIV and hepatitis C. These are highly prevalent in people who inject drugs, and have huge impacts on people’s health. SSTIs, abscesses and cellulitis mostly, receive far less focus even though these are quite common.
Mental health harms have become synonymous with people who use methamphetamines. However, individual study results are often inconsistent. This this has made it difficult to draw firm conclusions about the risks.
You probably wouldn’t be surprised to hear that people who use heroin, methamphetamine or crack cocaine are heavy users of emergency departments. The daily challenges of using these drugs mean that appointment-only services are difficult to navigate, and health is not always the top priority. Hospital-based studies appear to support this view, showing that frequent patients often use drugs and alcohol.
In the last twenty years there have been substantial increases in the use of pharmaceutical opioids in many countries, including Australia which has one of the highest levels of opioid utilisation globally 1. Almost 15 million opioid prescriptions were dispensed in 2015 and our use of high-potency opioids has also increased 2. One of the main drivers is the increased use of prescription opioids for chronic non-caner pain (CNCP) 3. In parallel to escalating use, opioid-related harms have also increased.
The advent of novel extended release depot buprenorphine formulations has the potential to transform opiate substitution therapy in a variety of settings and benefit the lives of people living with opioid dependence. CoLAB is an open-label cohort study of depot buprenorphine evaluating patient outcomes and process, and cost implications in a variety of models of care.